针对视网膜病变的抗VEGF大分子的局部输送:一篇综述
Varaprasad R Regu1, Ranjit P Swain2, Lolly Pattnaik3
1Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar 751003, Odisha, India.
International journal of biological macromolecules
|May 14, 2025
概括
对糖尿病视网膜病变的局部抗VEGF治疗有希望,但面临着交付挑战. 细胞透和脂质体等新策略旨在改善眼部药物透和持续释放,以获得更好的患者结果.
科学领域:
- 眼科医生 眼科 眼科
- 生物技术是生物技术.
- 药物运输 药物运输 药物运输
背景情况:
- 糖尿病视网膜病变 (DR) 是由于微血管并发症导致视力丧失的主要原因.
- 局部生物药物,特别是抗VEGFs,为DR提供比类固醇更好的结果,但已批准的方法具有侵入性,影响患者的遵守.
- 目前的非侵入性抗VEGF输送方法在稳定性和眼球透方面扎.
研究的目的:
- 探索用于糖尿病视网膜病变的抗VEGF生物药物的非侵入性局部输送的先进策略.
- 为了应对稳定性,透性和眼部生物制剂的控制释放方面的挑战.
- 调查细胞透,脂质体和膜载体向增强视网膜药物递送的潜力.
主要方法:
- 对眼部疾病的局部生物输送进行当前研究的综述.
- 对细胞透的使用作为生物药物的载体的研究.
- 探索脂质体配方,以提高极地生物的透率.
- 考虑向内源性膜载体,以改善眼部药物吸收.
主要成果:
- 穿透细胞的酸在传递生物制剂方面显示出令人鼓舞的结果.
- 脂质体封装提供了由于脂质性和小尺寸的视网膜访问的潜力.
- 控制释放仍然是局部眼部生物学的重大挑战.
- 准膜载体是提高药物透性的可行策略.
结论:
- 针对DR的非侵入性局部输送抗VEGFs需要创新的稳定性和透性的解决方案.
- 脂质体和细胞透是有前途的载体,但控制释放机制需要进一步开发.
- 利用眼睛的自然膜运输系统为改善眼部药物输送和治疗疗效提供了一条新的途径.
相关概念视频
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...